Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy

ConclusionsIn this patient affected by C3G, pioglitazone proved effective in reducing proteinuria levels.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research